一份最新的评论总结了通过向NF-kB通路来制黄类药物的抗癌潜力
Pratibha Pandey1, Sorabh Lakhanpal2, Danish Mahmood3
1Centre for Research Impact and Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, Punjab, India.
Frontiers in pharmacology
|January 21, 2025
概括
来自植物的黄类药物通过抑制核因子-卡帕B (NF-κB) 信号通路,在癌症治疗中显示出有前途. 这些化合物向关键的癌症过程,如瘤进展和转移.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 核因子-kappa B (NF-κB) 信号通路对于调节细胞生存,生长和迁移至关重要.
- 对NF-κB信号的失调有助于不受控制的细胞增殖,活力,运动和入侵,推动瘤的发展.
- 来自植物的植物化学物质,特别是黄类,以其抗氧化,抗炎,抗病毒和抗瘤的特性而闻名.
研究的目的:
- 概述NF-κB途径在瘤进展,耐药性,血管新生和转移中促进癌症的作用.
- 通过它们对NF-κB通路的特定向来总结黄类药物的抗癌潜力.
主要方法:
- 关于癌症NF-κB信号传导的当前研究的综述.
- 对黄类药物发挥抗癌作用的机制的分析,重点关注NF-κB抑制.
- 关于黄类药物作为向癌症治疗的综合文献综述.
主要成果:
- NF-κB通路放松调节与癌症发展和进展的关键方面有关.
- 黄类药物通过抑制NF-κB信号传递,显示出显著的抗癌潜力.
- 黄素的抗氧化和免疫调节作用是它们抗瘤作用的关键机制.
结论:
- NF-κB通路是癌症治疗的重要目标.
- 黄类化合物代表了癌症治疗的有前途的自然化合物,因为它们有抑制NF-κB信号传递的能力.
- 对向NF-κB的黄类药物的进一步研究可能会导致新的癌症疗法.
相关概念视频
NF-κB-dependent Signaling Pathway
7.2K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.2K
Cancer Prevention
6.0K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
6.0K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Positive Regulator Molecules
105.7K
To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
105.7K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K


